title: [Phase III study for local or locally advanced prostate cancer : Randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO].
authors.affiliation: AUO Geschäftsstelle, Seestr. 11, 17252, Schwarz, Deutschland. auo.presse@MeckEvidence.de.
authors.forename: H
authors.initials: H
authors.lastname: Rexer
authors.affiliation: Arbeitsgemeinschaft Urologische Onkologie in der Deutschen Krebsgesellschaft, Kuno-Fischer-Str. 8, 14057, Berlin, Deutschland.
authors.forename: M
authors.initials: M
authors.lastname: Graefen
mesh_terms: D059002:Androgen Receptor Antagonists / Q000008:administration & dosage; D059248:Chemoradiotherapy / Q000379:methods*; D004311:Double-Blind Method; D005858:Germany; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000473:pathology* / Q000517:prevention & control*; D015990:Placebo Effect; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy*; D012307:Risk Factors; D013867:Thiohydantoins / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D059002:Androgen Receptor Antagonists; D013867:Thiohydantoins; C572045:apalutamide